Harvard Apparatus Regenerative Technology Schedules Investor Teleconference for December 23, 2014, at 11:00 A.M. ET
Business Wire - Mon Dec 22, 1:19PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will hold a conference call to discuss recent events at 11:00 AM (Eastern Time) on December 23, 2014. On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 11:49AM CST
MPET: 0.92 (+0.02), EOPN: 9.37 (-0.02), AVAV: 27.39 (-0.11), NRX: 4.67 (+0.03), VSR: 3.01 (-0.03), MCOX: 3.11 (-0.01), SDRL: 11.90 (+0.04), NADL: 1.68 (-0.08), PDII: 1.63 (-0.01), CUB: 53.41 (-0.09), HKTV: 9.20 (+0.01), SOL: 1.48 (+0.03), VEEV: 26.88 (+0.25), DO: 38.66 (-0.62), IDRA: 3.89 (+0.02), TITN: 13.96 (-0.31), VGGL: 2.89 (+0.04), HART: 3.10 (-0.05), LIQD: 0.40 (-0.34), CTRP: 45.00 (-0.12)
Harvard Apparatus backs out of Russia
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 7:23AM CST
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU
Business Wire - Wed Nov 26, 6:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea announced that it will no longer be providing its HART-Trachea product for future transplant procedures performed at Krasnodar, Russia as part of the ongoing airway transplant studies there. HART will continue to focus primarily on completing preclinical work necessary to initiate clinical trials for its HART-Trachea product in the EU and U.S. It has made recent progress in the U.S. and EU, including the granting of orphan designation by the U.S. Food and Drug Administration (FDA) and a productive meeting with the Medicines and Healthcare Products Regulatory Agency of the U.K. (MHRA, the equivalent of the FDA in the U.K.). HART anticipates that during 2015 it will file its Investigational New Drug application to initiate a U.S. clinical trial and a Clinical Trial Authorization application to initiate an EU clinical trial.
HART: 3.10 (-0.05)
I'm Selling Harvard Apparatus Regenerative Technology
Jim Royal, The Motley Fool - Motley Fool - Tue Nov 18, 8:27AM CST
It's time to sell Harvard Apparatus Regenerative Technology . My Special Situations portfolio acquired shares in the speculative research and development company before it was spun off from Harvard Bioscience last year. Why sell? In...
HBIO: 5.15 (-0.09), HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:46AM CST
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Reports Operating Results for the Third Quarter Ended September 30, 2014
Business Wire - Thu Nov 06, 6:01AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
HART: 3.10 (-0.05)
The Company That Can Grow You A New Organ: A Promising Long-Term Investment
Daniel Kohlsdorf - Seeking Alpha - Thu Oct 30, 10:37AM CDT
About the company and its opportunities Harvard Apparatus Regenerative Technology (NASDAQ: HART ) makes the equipment used to create a new human trachea (breathing pipe) using the patient's own bone marrow cells. People who currently need a...
HBIO: 5.15 (-0.09), HART: 3.10 (-0.05)
HART reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:01AM CDT
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2014 Financial Results and Investor Teleconference for November 6, 2014
Business Wire - Mon Oct 27, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its third quarter ended September 30, 2014 before market trading hours on Thursday, November 6, 2014. A conference call to discuss the company's third quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Updates Patient Status
Business Wire - Fri Oct 17, 7:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away. The Company has not been informed of the cause of death. The patient survived more than two years from the initial regenerated trachea transplant surgery that took place in 2012. Prior to that surgery, the patient had suffered several instances of life threatening respiratory failure and infections. The patient was indicated for the initial transplant surgery because there was both a progression of the respiratory failure and traditional tracheal surgery was impossible.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea
Business Wire - Fri Sep 05, 1:51PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the HART-Trachea, which is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Reports Operating Results for Second Quarter Ended June 30, 2014
Business Wire - Fri Aug 08, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and six months ended June 30, 2014.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Schedules Release of Second Quarter 2014 Financial Results and Investor Teleconference for August 8th
Business Wire - Fri Aug 01, 3:00PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its second quarter ended June 30, 2014 before market trading hours on Friday, August 8, 2014. A conference call to discuss the company's second quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology's HART-Trachea Spotlighted in NBC-TV News Special on June 27
Business Wire - Mon Jun 30, 6:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces its HART-Trachea was spotlighted in a two-hour-long NBC-TV News Special on Friday, June 27.
HART: 3.10 (-0.05)
Harvard Apparatus Regenerative Technology Collaboration with Texas Heart Institute Profiled by Houston's NBC-TV Affiliate on February 19
Business Wire - Wed Feb 26, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured February 19 in a television segment and article reported by the NBC-TV affiliate in Houston (KPRC-TV).
HART: 3.10 (-0.05)